LakeShore Biopharma (LSBCF) AI Stock Analysis

• Market Cap: $33.80M
• Dividend Yield: N/A
• Average Volume (3M): 25.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.68
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 758
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 41,212,692
• 10 Day Avg. Volume: 2,430
• 30 Day Avg. Volume: 25,934
• PEG Ratio: 0.25
• Price to Book (P/B): 3.80
• Price to Sales (P/S): 3.09
• P/FCF Ratio: -13.69
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $1.00 ▲(29.87% Upside)

LakeShore Biopharma's overall stock score is primarily impacted by its financial performance, which shows strong gross profit margins but significant challenges with profitability and cash flow. Technical analysis indicates a bearish trend, and the lack of valuation data further contributes to a lower score. The absence of earnings call and corporate events data means these components do not influence the score.

LakeShore Biopharma Business Overview & Revenue Model

Company Description

LakeShore Biopharma (LSB) is a leading biotechnology firm specializing in the research, development, and commercialization of innovative therapeutic solutions in the fields of oncology and autoimmune diseases. The company leverages advanced biopharmaceutical technologies to create novel drug candidates aimed at improving patient outcomes. LSB's portfolio includes a range of biologics and small molecule therapies, with a strong emphasis on precision medicine and personalized treatment regimens.

How the Company Makes Money

LakeShore Biopharma generates revenue primarily through the commercialization of its therapeutic products, which include sales of approved drugs and biologics. The company also engages in strategic partnerships and collaborations with larger pharmaceutical companies for co-development and licensing agreements, which provide significant upfront payments and ongoing royalties based on product sales. Additionally, LSB may receive funding through government grants and research contracts aimed at advancing its clinical trials and product development efforts. The combination of direct product sales, royalties from partnerships, and external funding sources contributes to LSB's overall revenue stream.

LakeShore Biopharma Financial Statement Overview

Summary

LakeShore Biopharma exhibits strong gross profit margins, but persistent losses and negative cash flows pose significant challenges. The company needs to focus on improving operational efficiency and profitability to enhance its financial health. While leverage management has improved, further efforts are required to stabilize cash flows and achieve sustainable growth.

Income Statement

LakeShore Biopharma shows a consistent gross profit margin above 75%, indicating strong product profitability. However, the company faces challenges with negative net profit margins and EBIT margins, reflecting ongoing losses. Revenue growth is positive, but the company needs to address its high operating losses to improve overall profitability.

Balance Sheet

The company's debt-to-equity ratio has improved over time, indicating better leverage management, yet it remains relatively high. The negative return on equity highlights ongoing profitability challenges. The equity ratio suggests a moderate reliance on equity financing, but the company needs to enhance its asset utilization and profitability.

Cash Flow

LakeShore Biopharma's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow to net income ratio is positive, indicating some efficiency in converting net income to cash, but the overall negative cash flow growth and coverage ratios highlight liquidity challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	577.33M	614.96M	573.42M	687.20M	502.95M	257.02M
Gross Profit	389.12M	507.19M	455.73M	533.84M	381.49M	197.36M
EBITDA	-315.55M	-48.54M	-368.66M	-76.80M	-67.20M	-116.78M
Net Income	-433.70M	-99.98M	-433.46M	-145.48M	-236.67M	-191.83M
Balance Sheet
Total Assets	1.51B	1.37B	1.51B	1.72B	201.03M	91.37K
Cash, Cash Equivalents and Short-Term Investments	246.35M	28.08M	246.35M	370.11M	271.07M	390.46M
Total Debt	424.46M	414.40M	424.46M	498.63M	380.59M	18.44M
Total Liabilities	927.82M	867.91M	927.82M	991.30M	20.35M	70.01K
Stockholders Equity	585.21M	499.75M	585.21M	728.45M	671.25M	776.60M
Cash Flow
Free Cash Flow	0.00	-138.84M	-339.48M	-239.52M	-299.55M	-351.49M
Operating Cash Flow	0.00	-120.98M	-295.23M	-182.47M	-613.23K	-246.61M
Investing Cash Flow	0.00	-17.01M	-44.25M	-56.98M	-298.92M	-104.24M
Financing Cash Flow	0.00	-3.58M	205.26M	317.45M	364.56M	739.26M

LakeShore Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.77
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSBCF, the sentiment is Positive. The current price of 0.77 is above the 20-day moving average (MA) of 0.76, above the 50-day MA of 0.77, and below the 200-day MA of 1.34, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.22 is Neutral, neither overbought nor oversold. The STOCH value of 40.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LSBCF.

LakeShore Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XCUR	48 Neutral	$26.72M	-2.50	-150.50%	―	-100.00%	64.16%
LSBCF	42 Neutral	$33.80M	―	―	―	―	―
KZR	42 Neutral	$44.60M	-0.63	-58.39%	―	-100.00%	28.44%
PYPD	41 Neutral	$61.05M	-1.00	-312.77%	―	―	61.18%
CASI	39 Underperform	$20.61M	-0.44	―	―	41.43%	-50.12%
RANI	32 Underperform	$171.05M	―	―	―	―	22.94%

LakeShore Biopharma Corporate Events

LakeShore Biopharma Announces Going-Private Transaction Agreement

On November 4, 2025, LakeShore Biopharma announced a definitive agreement for a going-private transaction through a merger with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. The merger values the company at approximately $37 million, offering a 15.4% premium over the closing share price on August 15, 2025. The transaction, expected to close in the first quarter of 2026, will result in LakeShore Biopharma becoming a privately held company, with its shares no longer listed on the OTC Pink Open Market. This strategic move is supported by major shareholders and aims to enhance the company’s operational flexibility and long-term growth potential.